Birinapant (TL32711)

Catalog No.S7015

For research use only.

Birinapant (TL32711) is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM in a cell-free assay, less potent to XIAP. Birinapant helps to induce apoptosis in latent HIV-1-infected cells. Phase 2.

Birinapant (TL32711) Chemical Structure

CAS No. 1260251-31-7

Selleck's Birinapant (TL32711) has been cited by 58 publications

Purity & Quality Control

Choose Selective IAP Inhibitors

Biological Activity

Description Birinapant (TL32711) is a SMAC mimetic antagonist, mostly to cIAP1 with Kd of <1 nM in a cell-free assay, less potent to XIAP. Birinapant helps to induce apoptosis in latent HIV-1-infected cells. Phase 2.
Targets
cIAP1 [1]
(Cell-free assay)
XIAP [1]
(Cell-free assay)
<1 nM(Kd) 45 nM(Kd)
In vitro

Birinapant binds with XIAP and cIAP1 with Kd of 45 and <1 nM, respectively. Birinapant induces cell death as a single agent in TRAIL-insensitive SUM190 (ErbB2-overexpressing) cells (IC50, ~300 nM), and significantly increases potency of TRAIL-induced apoptosis in TRAIL-sensitive SUM149 (triple-negative, EGFR-activated) cells. Birinapant causes rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation. [1] Birinapant in combination with TNF-α exhibits a strong antimelanoma effect in vitro. Birinapant in combination with TNF-α(1 ng/mL) inhibits the growth of human melanoma cell lines WTH202, WM793B, WM1366 and WM164 with IC50s of 1.8, 2.5, 7.9 and 9 nM, respectively, while neither compound is effective individually. Birinapant singly treatment induces inhibition on proliferation of WM9 cells with IC50 of 2.4 nM. Birinapant significantly inhibits the target protein cIAP1 and cIAP2 in these cell lines.[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PANC-1 NGnUToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\rOVAwOjByL{WwNEBvVQ>? NGfRcYQxNTl4IHi= NEGzW4FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NWjCPHVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVI6PjlpPkK2NlUzQTZ7PD;hQi=>
Molm13  MnfzSpVv[3Srb36gRZN{[Xl? M4\LW|IwOjBxMkCwJI5O M{i3UVI1KGh? NHnEZpVl\WO{ZXHz[ZMh[0mDUEGgZY5lNCC2bzDhJI12[2hibHXzd4VzKGW6dHXueEwh[0mDUEKsJIFv\CC[SVHQJJVv\GW{II\hdolwfXNiY3;u[Il1cW:wcx?= NIrUNlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyOlc5Pyd-MkS1NlY4QDd:L3G+
WTH202 NWfTU|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[1eXE4OiCq MVrJR|UxRTFwODDuUUwh[2:vYnnu[YQhf2m2aDCxcocwdWxiVF7GMe6y Ml;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEO2N|QoRjJ|NECzOlM1RC:jPh?=
WM793B M1vZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\PVJE4OiCq NVLpc49DUUN3ME2yMlUhdk1uIHPvcYJqdmWmIIfpeIghOW6pL33sJHRPTi4QsR?= NXH0UHh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM9 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LlVlczKGh? MVHJR|UxRTJwNDDuUS=> NW\SVmxIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM9 M{nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fDd|czKGh? NHjr[3dKSzVyPUKuO{BvVSxiY3;tZolv\WRid3n0bEAydmdxbXygWG5HNc7z NY\QSlRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM1366 NHPJcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO0e3hjPzJiaB?= M1m3TmlEPTB;Nz65JI5ONCClb33ibY5m\CC5aYToJFFv\y:vbDDUUmYu|rF? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRyM{[zOEc,OjN2MEO2N|Q9N2F-
WM164 NHjyZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHne4dEPzJiaB?= MnnWTWM2OD17IH7NMEBkd22kaX7l[EB4cXSqIEHu[{9udCCWTl[t{tE> NX\TbYVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
451Lu MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPpO|IhcA>? NIDlOldKSzVyPUG0MlIhdk1uIHPvcYJqdmWmIIfpeIghOW6pL33sJHRPTi4QsR?= NX75SXB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzRpPkKzOFA{PjN2PD;hQi=>
WM1341D M3;ibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LWeVczKGh? M1\UbGlEPTB;NUeuOkBvVSxiY3;tZolv\WRid3n0bEAydmdxbXygWG5HNc7z M1uyUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NECzOlM1Lz5{M{SwN|Y{PDxxYU6=
WM3130 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojGO|IhcA>? MmDITWM2OD14ND6zJI5ONCClb33ibY5m\CC5aYToJFFv\y:vbDDUUmYu|rF? NHzDWoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN|Y{PCd-MkO0NFM3OzR:L3G+
WM1985 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT1NVk4OiCq MVjJR|UxRTl5IH7NMEBkd22kaX7l[EB4cXSqIEHu[{9udCCWTl[t{tE> M3HENlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NECzOlM1Lz5{M{SwN|Y{PDxxYU6=
WM3854 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TZUlczKGh? NYDmUJh1UUN3ME2yNlYhdk1uIHPvcYJqdmWmIIfpeIghOW6pL33sJHRPTi4QsR?= NF3YNpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN|Y{PCd-MkO0NFM3OzR:L3G+
MDA-MB-231 M1LGUGN6fG:2b4jpZ4l1gSCjc4PhfS=> MVe3NkBpenN? MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBkUUGSL2jJRXAu\GWyZX7k[Y51KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuNFEh|ryPLh?= NVnkOFlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PFQ{QTNpPkK1OVg1Ozl|PD;hQi=>
A875 MmHLR5l1d3SxeHnjbZR6KGG|c3H5 MYK3NkBpenN? M3fIVmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFiLQWCt[IVx\W6mZX70JIh2dWGwIFG4O|Uh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IECuNFQh|ryPLh?= M3nOVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUi0N|k{Lz5{NUW4OFM6OzxxYU6=
Assay
Methods Test Index PMID
Western blot cIAP1 / cIAP2 / XIAP ; NF-κB(p65) / IκBa / Bcl-xl / NF-κB(p100) / p52 ; BIRC2 / ARC 24526787 25079338
Immunofluorescence Caspase 3/7 28665401
Growth inhibition assay Cell viability 28460471
In vivo Birinapant (30 mg/kg) treatment significantly induces abrogation of tumor growth in melanoma xenotransplantation models 451Lu with. [2]

Protocol (from reference)

Kinase Assay:[1]
  • Fluorescence polarization assay:

    The binding affinities of compounds to XIAP and cIAP1 are determined using a fluorogenic substrate and are reported as Kd values. Initially, the dissociation constant (Kd) for the fluorescently labeled modified Smac peptide (AbuRPF-K(5-Fam)-NH2; FP pep-tide) is determined using a fixed concentration of peptide (5 nM) and titrating varying concentrations of protein (0.075–5 μM in half log dilutions). The dose–response curves are produced by a nonlinear least squares fit to a single-site binding model using GraphPad Prism, with 5 nM of FP peptide and 50 nM of XIAP used in the assay. Various concentrations of Smac mimetics (100–0.001 μM in half log dilutions) are added to FP peptide:protein binary complex for 15 min at room temperature in 100μL of 0.1 M potassium phosphate buffer, pH 7.5, containing 100 mg/mL bovine c -globulin. Following incubation, the polarization values are measured on a multi-label plate reader using a 485 nm excitation filter and a 520 nm emission filter.

Cell Research:[2]
  • Cell lines: Human melanoma cell lines WM9
  • Concentrations: 1 nM-1 μM
  • Incubation Time: 3 days
  • Method: Cells are allowed to attach for 24 hours and subsequently incubated with Birinapant and/or TNF-α for 24 or 72 hours. Then MTS assay is conducted
Animal Research:[2]
  • Animal Models: Human melanoma xenografts 451Lu
  • Dosages: 30 mg/kg
  • Administration: 3 times per week intraperitoneally

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(123.92 mM)
Water Insoluble
Ethanol ''55 mg/mL

Chemical Information

Molecular Weight 806.94
Formula

C42H56F2N8O6

CAS No. 1260251-31-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(C(=O)N1CC(CC1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)CC6CC(CN6C(=O)C(CC)NC(=O)C(C)NC)O)O)NC(=O)C(C)NC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01681368 Terminated Drug: Birinapant (TL32711) Epithelial Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 15 2012 Phase 2
NCT01486784 Terminated Drug: Birinapant Acute Myelogenous Leukemia Abramson Cancer Center of the University of Pennsylvania November 2011 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Birinapant (TL32711) | Birinapant (TL32711) supplier | purchase Birinapant (TL32711) | Birinapant (TL32711) cost | Birinapant (TL32711) manufacturer | order Birinapant (TL32711) | Birinapant (TL32711) distributor